{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate median and upper limit number.","groupId":"OG000","lowerLimit":"6.87","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"4.17","upperLimit":"14.9","value":"11.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"HPV p-16 Positive"},{"categories":[{"measurements":[{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG000","lowerLimit":"26.71","upperLimit":"NA","value":"39.43"},{"comment":"Insufficient number of events to calculate upper limit number.","groupId":"OG001","lowerLimit":"2.79","upperLimit":"NA","value":"8.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"HPV p-16 Negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the Platinum Refractory subgroup with a response","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression or death. Approximately 63 Months","title":"Duration of Response (DOR) - Platinum Refractory Subgroup Based on HPV p-16 Status","type":"SECONDARY","unitOfMeasure":"Months"}